Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor


  • Potential conflict of interest: Dr. O'Brien is an inventor on patent applications filed by the National Cancer Institute for the IFNL4-ΔG (ss469415590) genotype-based test and for the IFNL4 protein. Dr. Morgan received grants from Bristol-Myers Squibb, Genentech, Gilead, Vertex, and Merck.

No abstract is available for this article.